Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia
Discover Medicine · 02.08.2026 · 3 (1)
DOI: 10.1007/s44337-026-00645-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Medicine, online erschienen am 02.08.2026. Verfasst von Karin P. Q. Oomen und 5 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Oomen, K. P. Q., Wreesmann, V. B., Waner, B. J., Waner, S., Waner, M., & O, T. M. (2026). Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia. Discover Medicine, 3(1). https://doi.org/10.1007/s44337-026-00645-1
Vancouver
Oomen KPQ, Wreesmann VB, Waner BJ, Waner S, Waner M, O TM. Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia. Discover Medicine. 2026;3(1). doi:10.1007/s44337-026-00645-1
BibTeX
@article{Oomen2026,
author = {Oomen, Karin P. Q. and Wreesmann, Volkert B. and Waner, Benjamin J. and Waner, Stefan and Waner, Milton and O, Teresa M.},
title = {Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia},
journal = {Discover Medicine},
year = {2026},
volume = {3},
number = {1},
doi = {10.1007/s44337-026-00645-1}
}
EUVIMED